<DOC>
	<DOCNO>NCT00244998</DOCNO>
	<brief_summary>RATIONALE : Estrogen may cause growth prostate cancer cell . Hormone therapy use fulvestrant may fight prostate cancer block use estrogen tumor cell . PURPOSE : This phase II trial study well fulvestrant work treat patient advanced prostate cancer .</brief_summary>
	<brief_title>Fulvestrant Treating Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine prostate-specific antigen objective response ( complete partial response ) rate &gt; 0.2 patient androgen-independent advanced prostate cancer treat fulvestrant . Secondary - Determine toxicity drug patient . OUTLINE : This open-label study . Patients receive fulvestrant intramuscularly day 0 , 14 , 28 . Courses repeat month absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically survival . PROJECTED ACCRUAL : A total 33 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma prostate Advanced disease Must androgenindependent prostate cancer meeting follow criterion : Evidence rise prostatespecific antigen ( PSA ) level absolute value ≥ 5 ng/mL base 2 measurement take ≥ 2 week apart ( measurement must do androgen deprivation [ orchiectomy luteinizing hormonerelease hormone ( LHRH ) analogue ] antiandrogen withdrawal ) Rising PSA require ≥ 28 day antiandrogen progestational therapy prostate cancer ( ≥ 42 day bicalutamide nilutamide ) Testosterone &lt; 50 ng/mL ( unless surgically castrate ) Measurable evaluable disease PSA elevation constitute evaluable disease PATIENT CHARACTERISTICS : Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC &gt; 3,000/mm^3 Neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8 g/dL ( transfusion epoetin alfa allow ) No bleed diathesis ( e.g. , disseminate intravascular coagulation clot factor deficiency ) Hepatic Bilirubin normal Gilbert 's disease bilirubin ≤ 3 time upper limit normal ( ULN ) allow absence etiology ( e.g. , hemolysisreticulocyte count &lt; 5 % ) liver function test normal SGOT and/or SGPT ≤ 2 time ULN INR &lt; 1.6 Renal Creatinine &lt; 2.5 mg/dL Cardiovascular No unstable cardiac disease require medication No new onset crescendo rest angina Stable exertional angina allow Other Fertile patient must use effective barrier contraception 3 month completion study treatment No active malignancy within past 2 year except nonmelanoma skin cancer superficial bladder cancer No history significant neurologic psychiatric disorder , include psychotic disorder , dementia , seizures No serious illness medical condition No active infection No known hypersensitivity active inactive excipients fulvestrant ( e.g. , castor oil mannitol ) PRIOR CONCURRENT THERAPY : Biologic therapy Prior retinoids , vaccine , cytokine consider cytotoxic allow Chemotherapy No 1 prior cytotoxic chemotherapy regimen More 3 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) No concurrent chemotherapy Endocrine therapy See Disease Characteristics Prior glucocorticoid , antiandrogens , progestational agent , estrogen , LHRH analogues consider cytotoxic allow At least 4 week since prior flutamide ( 6 week bicalutamide nilutamide ) Concurrent megestrol acetate allow stable dose ≤ 40 mg/day Concurrent androgen deprivation use LHRH analogue allow must continue study treatment orchiectomy require maintain castrate level testosterone Radiotherapy More 3 week since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics See Endocrine therapy Other Recovered prior therapy Prior cholecalciferol analogue , ketoconazole , aminoglutethimide , peroxisomeproliferationactivated receptorgamma agonist antagonist , PCSPES consider cytotoxic allow No prior longterm anticoagulation therapy ( antiplatelet therapy allow ) More 4 week since prior investigational drug No concurrent anticancer therapy ( e.g. , PCSPES ) No concurrent bisphosphonates unless receive stable dose study entry No concurrent therapy may alter androgen metabolism androgen level No concurrent full anticoagulation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>